Molecular Partners AG

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 8.73%147.660.0%$994.17m
AMGNAmgen, Inc. 0.87%255.261.5%$856.48m
GILDGilead Sciences, Inc. 0.51%64.801.0%$543.24m
VRTXVertex Pharmaceuticals, Inc. 1.51%273.731.9%$497.98m
REGNRegeneron Pharmaceuticals, Inc. 1.37%692.802.6%$444.80m
ILMNIllumina, Inc. 5.95%258.063.3%$337.13m
NVAXNovavax, Inc. 17.46%55.2975.7%$314.14m
BIIBBiogen, Inc. 0.97%206.201.8%$237.64m
BNTXBioNTech SE 5.57%166.960.0%$224.59m
SNSSSunesis Pharmaceuticals, Inc. 2.38%2.150.7%$150.29m
EXASEXACT Sciences Corp. 7.96%53.8317.7%$134.25m
TECHBio-Techne Corp. 5.81%386.564.5%$107.96m
TXG10X Genomics, Inc. 11.91%52.990.0%$106.79m
BMRNBioMarin Pharmaceutical, Inc. 2.68%80.974.2%$95.42m
CRSPCRISPR Therapeutics AG 5.63%58.340.6%$85.42m

Company Profile

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.